Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Metastatic Lung Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The metastatic lung...
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Advanced Melanoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The advanced melanoma market has demonstrated robust...
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Paraganglioma Market Report 2026" has been added to ResearchAndMarkets.com's offering.The paraganglioma market is on an upward trajectory, with...
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "AI in Oncology for Analytical Solutions Market Report 2026" has been added to ResearchAndMarkets.com's offering. The AI in oncology for...
-
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Oncology Devices Market Report 2026" has been added to ResearchAndMarkets.com's offering.The oncology devices market has witnessed significant...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Pelvic Cancer Induced Hemorrhagic Cystitis Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pelvic cancer induced...
-
New oncologist formulated supplement systems aim to simplify wellness while addressing safety, dosing, and formulation challenges many survivors face.
-
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with HGSOC
-
Tidewave Bio appoints Prof. Alexander Eggermont as Head of Clinical Advisory Board to advance its biopsy-native immunotherapy for solid tumors.
-
Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer